Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Project Information

SHIGETECVAX

Grant agreement ID: 815568

DOI 10.3030/815568

EC signature date 30 April 2019

Start date 1 September 2019

End date 28 February 2025

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 0,00

EU contribution € 8 603 989,93

Coordinated by

EUROPEAN VACCINE INITIATIVE E.V
Germany

Deliverables

Open Research Data Pilot (1)

ORPD: Open Research Data Pilot

tbc

Documents, reports (1)

Composition of the SEAC incl. an ethics advisor

Composition of the SEAC incl an ethics advisor

Websites, patent fillings, videos etc. (1)

SHIGETECVAX web site

SHIGETECVAX web site established and launched

Publications

Peer reviewed articles (1)

Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial

Author(s): Girardi, Petra, Shushan Harutyunyan, Irene Neuhauser, Katharina Glaninger, Orsolya Korda, Gábor Nagy, Eszter Nagy, Valéria Szijártó, Denes Pall, Krisztina Szarka, Gábor Kardos, Tamás Henics, and Frank J. Malinoski
Published in: Vaccines, 2022, ISSN 2076-393X
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines10020340